You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Colorcon
Moodys
McKinsey
McKesson

Last Updated: August 5, 2020

DrugPatentWatch Database Preview

AZACTAM Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Azactam, and what generic alternatives are available?

Azactam is a drug marketed by Bristol Myers Squibb and is included in two NDAs.

The generic ingredient in AZACTAM is aztreonam. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the aztreonam profile page.

US ANDA Litigation and Generic Entry Outlook for Azactam

A generic version of AZACTAM was approved as aztreonam by FRESENIUS KABI USA on June 18th, 2010.

  Start Trial

Drug patent expirations by year for AZACTAM
Drug Prices for AZACTAM

See drug prices for AZACTAM

Recent Clinical Trials for AZACTAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eastern Virginia Medical SchoolPhase 2
Virginia Commonwealth UniversityPhase 2

See all AZACTAM clinical trials

Pharmacology for AZACTAM

US Patents and Regulatory Information for AZACTAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb AZACTAM aztreonam INJECTABLE;INJECTION 050580-002 Dec 31, 1986 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Bristol Myers Squibb AZACTAM IN PLASTIC CONTAINER aztreonam INJECTABLE;INJECTION 050632-003 May 24, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Bristol Myers Squibb AZACTAM aztreonam INJECTABLE;INJECTION 050580-003 Dec 31, 1986 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Bristol Myers Squibb AZACTAM aztreonam INJECTABLE;INJECTION 050580-001 Dec 31, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Colorcon
Johnson and Johnson
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.